Artem Smirnov

TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019.

TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019.

TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019.

TAE Life Sciences LLC is a privately-held biotechnology company that is developing a new biologically-targeted radiation therapy based on boron neutron capture therapy (BNCT). The company is based in Foothill Ranch, CA. The company is committed to developing next-generation targeted boron drugs and a low-energy accelerator-based neutron source that can treat patients with the most aggressive and recurrent cancers. TAE Life Sciences' Alphabeam™ neutron system and targeted boron drugs are currently in development and have not been approved for sale. Robert W. Hill has been the CEO of the company since 2019.